<DOC>
	<DOC>NCT01091818</DOC>
	<brief_summary>Dexmedetomidine will be tested against midazolam in a prospective, randomized, double-blind study of intensive care children, age 2-17 years. The investigators' primary hypothesis is that time from end of medication to extubation will be shorter with dexmedetomidine sedation.</brief_summary>
	<brief_title>Dexmedetomidine Versus Midazolam for Intensive Care Sedation of Children</brief_title>
	<detailed_description />
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Hypnotics and Sedatives</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>informed consent from parents age between 2 and 18 years anticipated need of respirator treatment for more than 24 hrs included in study within 48 hrs of admission to intensive care unit (ICU) severe, unstable circulatory failure severe intracranial or spinal trauma with circulatory instability sever bradycardia or atrioventricular (AV) block liver failure less than 50% chance of anticipated survival known allergy to study drugs</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>To see if sedation with dexmedetomidine results in faster emergence after end of intensive care treatment in children</keyword>
	<keyword>treatment</keyword>
</DOC>